Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

BACKGROUND: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive ri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Erbe, Amy K., Wang, Wei, Carmichael, Lakeesha, Hoefges, Anna, Grzywacz, Bartosz, Reville, Patrick K., Ranheim, Erik A., Hank, Jacquelyn A., Kim, KyungMann, Seo, Songwon, Mendonca, Eneida A., Song, Yiqiang, Kenkre, Vaishalee P., Hong, Fangxin, Gascoyne, Randy D., Paietta, Elisabeth, Horning, Sandra J., Miller, Jeffrey S., Kahl, Brad, Sondel, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419437/
https://ncbi.nlm.nih.gov/pubmed/30871628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0538-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados